GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | Map1lc3b | increases lipidation | EXP | | 6480464 | CTD | Resveratrol results in increased lipidation of MAP1LC3B protein | PMID:32619457 | Map1lc3b | multiple interactions | EXP | | 6480464 | CTD | [Benzo(a)pyrene co-treated with Resveratrol] promotes the reaction [MAP1LC3B protein binds to TOMM20 protein]; Resveratrol promotes the reaction [Benzo(a)pyrene results in increased lipidation of MAP1LC3B protein]; Resveratrol promotes the reaction [MAP1LC3B protein binds to TOMM20 protein] | PMID:32619457 | Map1lc3b | affects metabolic processing | ISO | MAP1LC3B (Homo sapiens) | 6480464 | CTD | resveratrol affects the metabolism of MAP1LC3B protein | PMID:23680031 | Map1lc3b | increases expression | ISO | MAP1LC3B (Homo sapiens) | 6480464 | CTD | resveratrol results in increased expression of MAP1LC3B mRNA; resveratrol results in increased expression of MAP1LC3B protein alternative form | PMID:23750556 PMID:24145604 | Map1lc3b | increases expression | ISO | Map1lc3b (Mus musculus) | 6480464 | CTD | resveratrol results in increased expression of MAP1LC3B mRNA | PMID:24095927 | Map1lc3b | increases lipidation | ISO | MAP1LC3B (Homo sapiens) | 6480464 | CTD | resveratrol results in increased lipidation of MAP1LC3B protein | PMID:26969377 | Map1lc3b | multiple interactions | ISO | MAP1LC3B (Homo sapiens) | 6480464 | CTD | 3-methyladenine inhibits the reaction [[TNF protein co-treated with Resveratrol] results in increased expression of MAP1LC3B protein alternative form]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [[TNF protein co-treated with Resveratrol] results in increased expression of MAP1LC3B protein alternative form]; [Doxorubicin co-treated with Resveratrol] results in increased lipidation of MAP1LC3B protein; [TNF protein co-treated with Resveratrol] results in increased expression of MAP1LC3B protein alternative form; ATG5 protein affects the reaction [[TNF protein co-treated with Resveratrol] results in increased expression of MAP1LC3B protein alternative form]; ATG5 protein affects the reaction [Resveratrol affects the metabolism of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [Resveratrol results in increased expression of MAP1LC3B protein alternative form]; BECN1 protein affects the reaction [[TNF protein co-treated with Resveratrol] results in increased expression of MAP1LC3B protein alternative form]; BECN1 protein affects the reaction [Resveratrol affects the metabolism of MAP1LC3B protein]; Chloroquine promotes the reaction [[TNF protein co-treated with Resveratrol] results in increased expression of MAP1LC3B protein alternative form]; dorsomorphin inhibits the reaction [Resveratrol affects the metabolism of MAP1LC3B protein]; Niacinamide inhibits the reaction [[TNF protein co-treated with Resveratrol] results in increased expression of MAP1LC3B protein alternative form]; Resveratrol promotes the reaction [[TNF protein co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein alternative form]; SIRT1 protein affects the reaction [[TNF protein co-treated with Resveratrol] results in increased expression of MAP1LC3B protein alternative form] | PMID:23680031 PMID:24145604 PMID:26969377 | Map1lc3b | multiple interactions | ISO | Map1lc3b (Mus musculus) | 6480464 | CTD | resveratrol promotes the reaction [Ethanol results in increased expression of MAP1LC3B mRNA] | PMID:24095927 | | ||||||||||||||||||||||
| Go Back to source page | Continue to Ontology report |